Filtered By:
Drug: Namenda

This page shows you your search results in order of relevance.

Order by Relevance | Date

Total 38 results found since Jan 2013.

Memantine Enhances Recovery From Stroke Basic Sciences
Conclusions— Our results suggest that memantine improves stroke outcomes in an apparently non-neuroprotective manner involving increased brain-derived neurotrophic factor signaling, reduced reactive astrogliosis, and improved vascularization, associated with improved recovery of sensory and motor cortical function. The clinical availability and tolerability of memantine make it an attractive candidate for clinical translation.
Source: Stroke - June 23, 2014 Category: Neurology Authors: Lopez-Valdes, H. E., Clarkson, A. N., Ao, Y., Charles, A. C., Carmichael, S. T., Sofroniew, M. V., Brennan, K. C. Tags: Animal models of human disease, Imaging, Other imaging, Other Stroke Treatment - Medical Basic Sciences Source Type: research

Memantine Treatment for Post-stroke Aphasia: A Case Control Study (P5.173)
CONCLUSION Memantine treatment showed no statistically significant improvement for patients with post-stroke aphasia based on FIM Scores for Motor and Cognition. Long-term follow-up and larger study groups, however, could provide additional information which may warrant further exploration into the benefits of memantine.Disclosure: Dr. Valles has nothing to disclose. Dr. Kennedy has nothing to disclose. Dr. Elashvili has nothing to disclose. Dr. Dohle has nothing to disclose.
Source: Neurology - April 8, 2015 Category: Neurology Authors: Valles, J., Kennedy, J., Elashvili, M., Dohle, C. Tags: Neuro-rehabilitation: Stroke Source Type: research

The dichotomy of memantine treatment for ischemic stroke: dose-dependent protective and detrimental effects
obert Fern
Source: Journal of Cerebral Blood Flow - November 19, 2014 Category: Neurology Authors: Melissa TrotmanPhilipp VermehrenClaire L GibsonRobert Fern Tags: glutamate ischemia memantine NMDA receptor stroke Source Type: research

The efficacy and safety of pharmacological treatments for post-stroke aphasia.
Conclusions Current evidence suggests that drugs can improve the prognosis of post-stroke aphasia, such as donepezil, memantine. Donepezil has a significant effect in improving the ability of auditory comprehension, naming, repetition and oral expression. Memantine has a significant effect in improving the ability of naming, spontaneous speech and repetition. Bromocriptine showed no significant improvement in the treatment of aphasia after stroke. The trial for galantamine, amphetamine and levodopa in the treatment of aphasia after stroke is limited and inconclusive. PMID: 29984673 [PubMed - as supplied by publisher]
Source: CNS and Neurological Disorders Drug Targets - July 6, 2018 Category: Drugs & Pharmacology Authors: Zhang X, Shu B, Zhang D, Huang L, Fu Q, Du G Tags: CNS Neurol Disord Drug Targets Source Type: research

Stroke as a cause of death in death certificates of patients with dementia: a cohort study from the Swedish Dementia Registry.
CONCLUSIONS: There was relatively high number of patients that died from IS in their death certificate but had not been registered in Riksstroke in the year before death. This creates concerns on the accuracy of death certificate stroke diagnoses, particularly for deaths taking place outside of hospitals. PMID: 30280666 [PubMed - as supplied by publisher]
Source: Current Alzheimer Research - October 2, 2018 Category: Neurology Authors: Subic A, Zupanic E, von Euler M, Norrving B, Cermakova P, Religa D, Winblad B, Kramberger MG, Eriksdotter M, Garcia-Ptacek S Tags: Curr Alzheimer Res Source Type: research

Memantine Attenuates Cell Apoptosis by Suppressing the Calpain-Caspase-3 Pathway in an Experimental Model of Ischemic Stroke.
Abstract Ischemic stroke, the second leading cause of death worldwide, leads to excessive glutamate release, over-activation of N-methyl-D-aspartate receptor (NMDAR), and massive influx of calcium (Ca(2+)), which may activate calpain and caspase-3, resulting in cellular damage and death. Memantine is an uncompetitive NMDAR antagonist with low-affinity/fast off-rate. We investigated the potential mechanisms through which memantine protects against ischemic stroke in vitro and in vivo. Middle cerebral artery occlusion-reperfusion (MCAO) was performed to establish an experimental model of ischemic stroke. The neuropr...
Source: Experimental Cell Research - January 5, 2017 Category: Cytology Authors: Chen B, Wang G, Li W, Liu W, Lin R, Tao J, Jiang M, Chen L, Wang Y Tags: Exp Cell Res Source Type: research

Abolition of aberrant neurogenesis ameliorates cognitive impairment after stroke in mice
Poststroke cognitive impairment is considered one of the main complications during the chronic phase of ischemic stroke. In the adult brain, the hippocampus regulates both encoding and retrieval of new information through adult neurogenesis. Nevertheless, the lack of predictive models and studies based on the forgetting processes hinders the understanding of memory alterations after stroke. Our aim was to explore whether poststroke neurogenesis participates in the development of long-term memory impairment. Here, we show a hippocampal neurogenesis burst that persisted 1 month after stroke and that correlated with an impair...
Source: Journal of Clinical Investigation - February 25, 2019 Category: Biomedical Science Authors: María Isabel Cuartero, Juan de la Parra, Alberto Pérez-Ruiz, Isabel Bravo-Ferrer, Violeta Durán-Laforet, Alicia García-Culebras, Juan Manuel García-Segura, Jagroop Dhaliwal, Paul W. Frankland, Ignacio Lizasoain, María Ángeles Moro Source Type: research

Pharmacotherapy to Enhance Cognitive and Motor Recovery Following Stroke
Abstract Stroke is a leading cause of disability among older adults and more than half of stroke survivors have some residual neurological impairment. Traditionally, managing the aftermath of stroke has been by the implementation of several physical and language therapy modalities. The limitations of these rehabilitation efforts have sparked an interest in finding other ways to enhance neurological recovery. Some of these novel approaches have included pharmacological interventions, cell-derived treatments, and cortical magnetic stimulation. Mounting evidence over the last 2 decades suggests that pharmacological ...
Source: Drugs and Aging - September 30, 2015 Category: Geriatrics Source Type: research

Targeting organic cation transporters at the blood-brain barrier to treat ischemic stroke in rats
Exp Neurol. 2022 Jul 26:114181. doi: 10.1016/j.expneurol.2022.114181. Online ahead of print.ABSTRACTDrug discovery and development for stroke is challenging as evidenced by few drugs that have advanced beyond a Phase III clinical trial. Memantine is a N-methyl-d-aspartate (NMDA) receptor antagonist that has been shown to be neuroprotective in various preclinical studies. We have identified an endogenous BBB uptake transport system for memantine: organic cation transporters 1 and 2 (Oct1/Oct2). Our goal was to evaluate Oct1/Oct2 as a required BBB mechanism for memantine neuroprotective effects. Male Sprague-Dawley rats (200...
Source: Experimental Neurology - July 29, 2022 Category: Neurology Authors: Joshua A Stanton Erica I Williams Robert D Betterton Thomas P Davis Patrick T Ronaldson Source Type: research

Stroke Rounds: Dementia Drug for Stroke Recovery?
(MedPage Today) -- The Alzheimer's disease drug memantine (Namenda) might be worth a look for improving recovery from stroke, a mouse-model study suggested.
Source: MedPage Today Cardiovascular - July 22, 2014 Category: Cardiology Source Type: news

Alzheimer's Drug May Enhance Stroke Recovery Alzheimer's Drug May Enhance Stroke Recovery
Memantine may improve stroke outcomes in a non-neuroprotective way, preliminary research suggests. Medscape Medical News
Source: Medscape Today Headlines - August 5, 2014 Category: Consumer Health News Tags: Neurology & Neurosurgery News Source Type: news

Bilateral brain reorganization with memantine and constraint-induced aphasia therapy in chronic post-stroke aphasia: An ERP study.
Abstract Changes in ERP (P100 and N400) and root mean square (RMS) were obtained during a silent reading task in 28 patients with chronic post-stroke aphasia in a randomized, double-blind, placebo-controlled trial of both memantine and constraint-induced aphasia therapy (CIAT). Participants received memantine/placebo alone (weeks 0-16), followed by drug treatment combined with CIAT (weeks 16-18), and then memantine/placebo alone (weeks 18-20). ERP/RMS values (week 16) decreased more in the memantine group than in the placebo group. During CIAT application (weeks 16-18), improvements in aphasia severity and ERP/RMS...
Source: Brain and Language - April 28, 2015 Category: Neurology Authors: Barbancho MA, Berthier ML, Navas-Sánchez P, Dávila G, Green-Heredia C, García-Alberca JM, Ruiz-Cruces R, López-González MV, Dawid-Milner MS, Pulvermüller F, Lara JP Tags: Brain Lang Source Type: research

A Beacon of Hope in Stroke Therapy - Blockade of Pathologically Activated Cellular Events in Excitotoxic Neuronal Death as Potential Neuroprotective Strategies
Publication date: Available online 17 February 2016 Source:Pharmacology & Therapeutics Author(s): Ashfaqul Hoque, M. Iqbal Hossain, Sadia Ameen, Ching-Seng Ang, Nicholas Williamson, Dominic C.H. Ng, Anderly Chueh, Carli Roulston, Heung-Chin Cheng Excitotoxicity, a pathological process caused by over-stimulation of ionotropic glutamate receptors is a major cause of neuronal loss in acute and chronic neurological conditions such as ischemic stroke, Alzheimer’s and Huntington’s diseases. Effective neuroprotective drugs to reduce excitotoxic neuronal loss in patients suffering from these neurological con...
Source: Pharmacology and Therapeutics - February 19, 2016 Category: Drugs & Pharmacology Source Type: research

A beacon of hope in stroke therapy—Blockade of pathologically activated cellular events in excitotoxic neuronal death as potential neuroprotective strategies
Publication date: Available online 17 February 2016 Source:Pharmacology & Therapeutics Author(s): Ashfaqul Hoque, M. Iqbal Hossain, S. Sadia Ameen, Ching-Seng Ang, Nicholas Williamson, Dominic C.H. Ng, Anderly Chueh, Carli Roulston, Heung-Chin Cheng Excitotoxicity, a pathological process caused by over-stimulation of ionotropic glutamate receptors, is a major cause of neuronal loss in acute and chronic neurological conditions such as ischaemic stroke, Alzheimer's and Huntington's diseases. Effective neuroprotective drugs to reduce excitotoxic neuronal loss in patients suffering from these neurological co...
Source: Pharmacology and Therapeutics - February 29, 2016 Category: Drugs & Pharmacology Source Type: research